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91. Introduction
Primaquine is the only FDA licensed therapy to treat relapsing strains
of malaria. These strains include Plasmodium vivax and PlasmodiumYP, Cytochrome P450; G6PD,
ing system; MOA, Monoamine
19 9449.
sisin.s@gmail.com
ss article under the CC BY-NC-ND liceovale and relapses are assumed to be caused by the re-activation of dor-
mant liver forms of the parasites called hypnozoites (Krotoski et al.,
1980), although, recent ﬁndings have prompted the reassessment of
the hypnozoite causal assumption of relapsing malaria (Markus,
2015). Primaquine is one of the prototypical molecules from the
8-aminoquinoline class of antimalarial compounds which was
developed by the US Army during World War II in efforts to reduce
the serious burden of malaria in combat troops in the paciﬁc theater.
Primaquine was ﬁrst synthesised in 1946 by Elderﬁeld and colleagues
at Columbia University (Elderﬁeld et al., 1946). Primaquine was ﬁrst
tested in humans as part of the US Governments Malaria Projectnse (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1948; Edgcomb et al., 1950). Primaquine was utilized throughout the
1950s during the Korean War where it was used to treat Plasmodium
vivax malaria (Garrison et al., 1952; Coatney et al., 1953; Di Lorenzo
et al., 1953; Jones et al., 1953). Primaquine has gone on to become the
standard therapy in treating relapsing malaria and an important tool
in malaria transmission blocking and elimination campaigns (Graves
et al., 2015).
The structure of primaquine is shown in Fig. 1. Themain component
of the primaquine structure is made up of the aromatic quinoline core.
The two substituents on the primaquine core are the methoxy group
at the 6-position, and the amino sidechain at the 8-position. It is this
unique structural combination of the 6 and 8 groups as well as the
electronic properties of primaquine (McChesney & Sarangan, 1984)
that result in the anti-hypnozoite activity of primaquine and related
8-aminoquinolines. These chemical and electronic properties of the
8-aminoquinoline core allow primaquine and other 8-aminoquinolines
to be metabolically activated in the right place and at the right time in
order to be efﬁcacious in humans infected with Plasmodium vivax. The
place is the human liver and the time is when liver-stage Plasmodium
hypnozoites are present. The metabolic event that is required to
eliminate Plasmodium hypnozoites is primaquine activation by CYP
2D6 metabolism. This efﬁcacy-metabolism link is a recent discovery by
the US Army at the Walter Reed Army Institute of Research and the
University of Mississippi (Pybus et al., 2012; Bennett et al., 2013; Pybus
et al., 2013; Deye & Magill, 2014). This review aims to place the recent
CYP 2D6 discovery in context with the current understanding of
primaquine pharmacology.
2. CYP 2D6 genetic variation and drug metabolism
CYP2D6 is a cytochromeP450 hepatic enzyme that is responsible for
themetabolism of 20%–25% of clinically used drugs (Zanger et al., 2004;
Kumar et al., 2012; Preissner et al., 2013; Zanger & Schwab, 2013). This
structural promiscuity is an important aspect of CYP 2D6 mediated
metabolism because despite the large number of CYP 2D6 substrates,
CYP 2D6 only constitutes a small percentage of total hepatic P450s
(Ingelman-Sundberg, 2005). CYP 2D6 catalyzes the oxidation of
molecules and prefers substrates that are lipophilic and contain a
protonatable nitrogen (e.g. primaquine, see (Guengerich, 2007) for the
catalytic cycle description). The enzymatic activity of CYP 2D6 can
vary greatly depending on the genetic background of an individual.
The existence of varying CYP 2D6 activity in humans was discovered
by several groups in the 1970s through observation of adverse reactions
and inter-individual variation of the pharmacokinetics of antihyperten-
sive as well as antiarrhythmic drugs [see (Mahgoub et al., 1977;
Eichelbaum et al., 1979; Meyer & Zanger, 1997) for more information].
The genetic reason for these observed polymorphic drug effects onPrimaquine 
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Fig. 1. Structure of primaquine. Shown is the structure of themolecule. The quinoline ring
is numbered for reference. Themethyl group located at the stero-center is indicated by the
asterisk. The 3-dimensional orientation of the methyl group at this stero-center is
responsible for the formation of the (R) (−) and (S) (+) enantiomeric pair (see text).pharmacokinetics was later identiﬁed in the late 1980s by several
groups [see (Eichelbaum et al., 1987; Gonzalez et al., 1988)]whereupon
it was determined that allelic variation in the CYP 2D6 gene was associ-
ated with the observed phenotypic effects. There are more than 46
known major CYP 2D6 alleles which can be classiﬁed as variants that
result in abolished, decreased, normal, or increased catalytic activity.
Human CYP 2D6 genes can easily be sequenced and the CYP 2D6 allelic
combination determined. Depending onwhat combination of alleles are
present (humans can havemultiple copies of the CYP 2D6gene), human
phenotypes can be predicted and classiﬁed as CYP 2D6 poor, intermedi-
ate, extensive, and ultra-rapid metabolizers [see (Crews et al., 2012,
2014) for classiﬁcation determination based on activity score]. These
classiﬁcations can predict an individual's pharmacokinetic and pharma-
codynamic responses to a therapeutic agent that ismetabolized through
the CYP 2D6 pathway. The extensive amount of research into CYP 2D6
over the last 40 years has provided a wealth of knowledge of how
drug pharmacology can be impacted by CYP 2D6. The subsequent
sections of this review discuss the various aspects of primaquine
pharmacology that are inﬂuenced by CYP 2D6 genetic variation.
3. Overview of primaquine metabolomics.
Although rigorously researched for decades, our understanding of
primaquine metabolomics has greatly expanded in the past 5 years.
The main concept that has been fully uncovered during this period is
that the parent primaquine molecule is a pro-drug which is converted
by CYP 2D6 to a(n) oxidized metabolite(s) which is (are) responsible
for the ensuing anti-hypnozoite activity. Recent technological advances
in liquid chromatography-mass spectrometry instrumentation
(Bateman et al., 2007; Spaggiari et al., 2014) have enabled extensive
metabolite identiﬁcation and CYP P450 phenotyping studies using
recombinant isoenzymes and/or hepatocytes. Pybus et al., 2012,
demonstrated that primaquine metabolism is largely driven through
two distinct pathways, namely CYP 2D6 and MAO-A. In an extensive
in vitro testing of primaquine, CYP 2D6, MAO-A, CYP 2C19, and CYP
3A4 (in order of catalytic efﬁciency) all showed the ability tometabolize
primaquine to some extent (Pybus et al., 2012). It should be noted that
CYP 2D6 displayed the highest Vmax/Km ratio (catalytic efﬁciency)
toward primaquine of all recombinant CYPs and MAOs tested. This
suggested that while CYP 2D6 is relatively low in concentration as
compared to other relevant CYPs in hepatocyte tissue, it's potential
physiologic relevance in the primaquine metabolic pathway is great.
TheMAO-A pathway seems largely responsible for the generation of
a primaquine aldehyde species (the likely progenitor of carboxy-
primaquine, the most abundant plasma metabolite in humans)
(Mihaly et al., 1984; Pybus et al., 2012). Interestingly, phenolic metabo-
lites, previously associated with redox activity (Vasquez-Vivar &
Augusto, 1992) were observed to be primarily the products of CYP
2D6 metabolism (Pybus et al., 2012). As further supportive evidence,
it was shown that exposure of phenolic metabolites decreased in CYP
2D knockout mice (Potter et al., 2015). A more complete illustration of
the observed metabolites of primaquine is shown in Fig. 2. Although a
complex mixture of metabolites are generated in vivo, in general they
can be thought of in two classes: 1) CYP generated phenolic metabolites
or 2) alcohols, aldehydes, and phase II conjugates thereof generated
through MAO/ADH dependent pathways as depicted in Fig. 3. In
addition to the already complex nature of primaquine metabolomics
discussed above, steroselectivity also plays a role in the metabolism
that occurs both in vitro and in vivo (Fasinu et al., 2014; Tekwani
et al., 2015).
4. CYP 2D6 metabolism effects on primaquine efﬁcacy
It has long been speculated that phenolicmetabolites, particularly 5-
hydroxyprimaquine, play some role in notable hemolytic toxicity of
primaquine (Vale et al., 2009). What was not known until recently
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Fig. 2.Metabolomics of primaquine. Shown are the various structures of documented primaquine metabolites as a result of hepatic metabolism. Phase I metabolites include phenolic
oxidations, carboxy derivatives, and quinone species. Phase II metabolites include glucose conjugates and other various glucuronide linkages (Phase II conjugate work from Fasinu
et al., 2016). Not all documented metabolites are shown. See (Vasquez-Vivar & Augusto, 1992, 1994; Garg et al., 2011; Pybus et al., 2012; Fasinu et al., 2014) for further metabolite
literature.
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Bennett et al. (2013) reported primaquine therapy failures from a Plas-
modium vivax challenge trial which were directly attributable to 2D6
polymorphisms of the intermediate or null phenotype. In an
additional study, Pybus et al. (2013) demonstrated the dependence of
primaquine efﬁcacy on CYP 2D metabolism in a malaria mouse model.
As illustrated in Fig. 4, primaquine exhibited no activity at a therapeutic
dose (20 mg/kg) when given to CYP 2D knockout mice challenged with
Plasmodium berghei (Pybus et al., 2013). In an attempt to link speciﬁc
metabolites to this effect, the known human CYP 2D6 inhibitor paroxe-
tine was pre-incubated with recombinant CYP 2D6 and primaquine
metabolite production monitored. Pre-incubation of CYP 2D6 with
paroxetine in vitro resulted in a marked reduction in the production of
the phenolic metabolites as previously noted (Pybus et al., 2013).
Interestingly, this CYP 2D effect in knockout mice drastically alters
the pharmacokinetics of primaquine. A more thorough discussion of
this topic can be found later in this review, but in summary, parentprimaquine exposure increased in knockout mice as compared to
wild-type, while phenolic metabolites levels drastically decreased
(Potter et al., 2015). In particular, a stable product of 5-hydroxy-
primaquine redox cycling, 5,6-orthoquinone, was used as a surrogate
marker for the presence of the unstable 5-hydroxyprimaquine. From
the knowledge gained from these studies, a proposed mechanism of
primaquine bio-activation and liver stage antimalarial action can be
constructed and is illustrated in Fig. 5. Primaquine hydroxylation via
CYP 2D6 creates unstable metabolites that are capable of redox cycling
and producing oxidative stress. The most studied of these metabolites
is 5-hydroxyprimaquine which can redox cycle to the corresponding
quinone-imine species as illustrated in Fig. 5. It is the resulting redox
cycling of these metabolites and oxidative stress produced from
primaquine metabolism that is believed to be the likely causative
agent for primaquine efﬁcacy, as well as primaquine hemolytic toxicity.
As we will discuss further, primquine's dependence on 2D metabo-
lism for efﬁcacy raises obvious concerns about efﬁcacy in polymorphic
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Fig. 3. Primaquine CYP 2D6 and MAO-Amediatedmetabolic pathways. The primaquine aldehyde and subsequent carboxy metabolite formed throughMAO-Ametabolism is highlighted
by the blue box. The primaquine phenolic metabolites produced through CYP 2D6 metabolism are highlighted by the red box. Phase II metabolites of primaquine are not shown.
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allelic variants (Ingelman-Sundberg, 2005), and large populations of in-
dividuals in malaria endemic areas are thought to be affected with
intermediate or null phenotypes (Kitada, 2003; Bains, 2013). With
these facts in hand, it is clear that primaquine usage as a radical curative
agent; prophylactic agent for travel, or in combinations for large-scale
eradication efforts needs to be done with careful consideration of both
the pharmacogenomic issues of the drug aswell as the problems related
to its toxicity.
5. CYP 2D6 metabolism and primaquine toxicity
Primaquine therapy is not without its risks. Humans that are G6PD
deﬁcient and have a reduced capacity to mitigate cellular damage as a
result of oxidative damage are susceptible to primaquine induced
hemolysis. Primaquine induced hemolysis is characterized by severe
anemia, intravascular hemolysis with dark urine, and mild jaundice
(Claymanet al., 1952; Hockwald et al., 1952; Ashley et al., 2014). Clinical
manifestations of hemolysis depend largely on the primaquine dose
administered and severity of the individual's G6PD deﬁciency
(Cappellini & Fiorelli, 2008; Ashley et al., 2014). The subsequent sectionreviews the current literature and knowledge of primaquine hemolytic
toxicity in the context of CYP 2D6/hepatic metabolism.
The exact mechanism by which primaquine exerts its hemolytic
effects and how/if CYP 2D6 metabolism plays a role in these effects
remains to be determined. There have been numerous groups that
have studied both the in vitro and in vivo hemolytic effects of
primaquine (Hong et al., 1992; Vasquez-Vivar & Augusto, 1992; Morais
Mda & Augusto, 1993; Vasquez-Vivar & Augusto, 1994; Bolchoz et al.,
2001; Bowman et al., 2004; Ganesan et al., 2009; Garg et al., 2011).
Similar to primaquine liver stage efﬁcacy, primaquine induced damage
to red blood cells and cellular components does appear to require
hepatic metabolism (Ganesan et al., 2009; Xuan et al., 2015). Ganesan
et al. conducted a series of in vitro metabolic incubations with
primaquine, microsomes/recombinant CYPs, and human erythrocytes.
The oxidative stress markers ROS and methemoglobin formation were
monitored for the various incubations and it was determined using
both microsomal preparations and recombinant CYP isoforms that
primaquine required metabolism to exert hemotoxic effects. Proﬁling
primaquine oxidative damage with regard to each CYP isoform tested
(CYP 1A2, 2B6, 3A4, 2D6, 2E1) indicated that multiple CYP enzymes
are capable of catalyzing primaquine mediated oxidative stress in vitro.
CYP 2D KO +
20 mg/kg PQ
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A B
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Fig. 4. Primaquine efﬁcacy in wild-type and CYP 2D deﬁcient mice. A. IVIS images of mice infected with luciferase expressing Plasmodium berghei parasites 24 and 72 h post infection.
Bioluminescence indicates infection. Liver stage infections can be observed 48 h post infection, while systemic infection is observed 72 h post infection. The image in Fig. 4 (A.)
illustrates an infection control. (B.) Liver stage activity of primaquine in wild-type mice given Plasmodium berghei. Wild-type (WT) mice given three daily 20 mg/kg doses of
primaquine over 3 days never develop mouse malaria. (C.) The same dose of primaquine given to mice that are deﬁcient in metabolizing CYP 2D6 substrates (CYP 2D knockout). CYP
2D knockout mice develop both liver stage and systemic infection despite primaquine therapy indicating metabolic activation is required for primaquine activity. Figure adapted from
(Pybus et al., 2013).
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the hemolytic potential of speciﬁc chemically synthesized phenolic me-
tabolites of primaquine (Allahyari et al., 1984; Hong et al., 1992;
Vasquez-Vivar & Augusto, 1992; Vasquez-Vivar & Augusto, 1994;
Bowman et al., 2004). The work of Vasquez-Vivar et al., Hong et al.,
and Bowman et al. studied the oxidative and hemolytic potential of 5-
hydroxyprimaquine and other phenolic derivatives (Vasquez-Vivar &
Augusto, 1992, 1994; Bowman et al., 2004). Recently, the production
of 5-hydroxy- primaquine and other phenolic derivatives of has been
shown to be CYP 2D6 dependent ( Pybus et al., 2012, 2013; Potter
et al., 2015). It has long been established that 5-hydroxy-primaquine
and subsequent oxidized products such as quinone-imine intermediates
are unstable in environments where oxygen is not rigorously excluded
(5-hydroxyprimaquine t1/2(buffer) = 45 s, t1/2(buffer + red blood cells) =
30 s) and was shown to be directly hemolytic both in vitro and in vivo.•H2O2 Productio
•Possible Pr
•Parasite
Unstable 
Fig. 5. Proposed mechanism of primaquine CYP 2D6 metabolic activation and liver stage antim
primaquine has little to no liver stage antimalarial activity. CYP 2D6 hydroxylates primaquin
produces and unstable intermediate. The 5-hydroxyprimaquine is capable of redox cycling b
produce H2O2, ROS, and subsequent oxidative damage. The 5-hydroxyprimaquine and corresp
the stable 5,6-ortho-quinone.Such studies were challenging to conduct due to the oxidative liability
of 5-hydroxyprimaquine. Vasquez-Vivar et al. examined the oxidative
capability of 5-hydroxy-primaquine to oxidize rat hemoglobin using
light absorption spectroscopy, oxygen consumption studies, and electron
paramagnetic resonance spectroscopy. Vasquez-Vivar et al. suggested
from their studies that hydrogen peroxide (H2O2) was the main oxida-
tive agent responsible for the hemotoxic effects reported. The redox
cycling of 5-hydroxy primaquine and derivatives is thought to result in
H2O2 production (Vasquez-Vivar & Augusto, 1992, 1994). This hypothe-
sis is consistent with several other studies (Vasquez-Vivar & Augusto,
1992, 1994; Bolchoz et al., 2001) and indicates that CYP 2D6 dependent
phenolic metabolites (e.g.5-hydroxy primaquine) are likely responsible
for primaquine induced hemolytic toxicity. Additionally, these reactive
metabolites have the potential to form direct adducts with free thiols
and other reactive groups as noted by Garg et al., 2011. It is highly likelyn, Oxidative Stress
otein Adduction
 Destruction
Unstable 
alarial activity. Shown is the proposed mechanism of activation by CYP 2D6. Unmodiﬁed
e on multiple locations of the quinoline core, however, hydroxylation at the 5-position
ack and forth to the corresponding quinone-imine. This redox cycle has been shown to
onding quinone-imine species are inherently unstable and will react with water to form
6 S.R. Marcsisin et al. / Pharmacology & Therapeutics 161 (2016) 1–10that 5-hydroxy primaquine is involved in the mechanism of hemolytic
toxicity, either directly; bymeans of highly reactive transient metabolite
species, or as a result of oxidative by products such as hydrogen peroxide
resulting from the redox cycling of the 5-hydroxyprimaquine/5,8-
quinone imine redox pair. Despite the intensive research efforts by
numerous groups toward understanding primaquine toxicity, the exact
enzyme(s) and metabolic pathway(s) involved with 8-aminoquinoline
inducedhemolysis still remain to be fully elucidateddue to the instability
and transient nature of the primaquine phenolic metabolites emanating
from 5-hydroxyprimaquine. The responsible metabolite(s) and path-
way(s) will likely have to be determined using transgenic CYP knockout
mouse models (Scheer et al., 2012) adapted for testing of hemolytic
toxicity of human red blood cells (Rochford et al., 2013).
6. CYP 2D6 metabolism and primaquine pharmacokinetics
The pharmacokinetics of primaquine have been proﬁled in multiple
species over the years to include numerous human clinical studies
(Fletcher et al., 1981; Mihaly et al., 1984, 1985; Prasad et al., 1985;
Ward et al., 1985; Bennett et al., 2013; Pukrittayakamee et al., 2014;
Jittamala et al., 2015; Potter et al., 2015). Primaquine taken orally
reaches the maximum concentrations in human plasma 1–2 h after
ingestion. Primaquine is rapidly metabolized and has short plasma
elimination half-life (human t1/2 ~ 4 h, mice t1/2 ~ 1.5 h). The pharmaco-
kinetic parameters of primaquine change signiﬁcantly in human and
mouse models of differential CYP 2D6 metabolism. Bennett et al.'s
(2013) human challenge vivax study assessed the plasma pharmacoki-
netics of primaquine and carboxyprimaquine from both individuals
who were relapse free, and individuals who relapsed from Plasmodium
vivax infection. Individuals who relapsed were genotyped and it was
determined that they fell into the predicted poor/intermediate
metabolizer phenotype classiﬁcation. These subjects had higher parent
primaquine exposure (AUCinf), longer elimination half-lives of parent
molecule (t1/2), lower apparent clearance values (CL/F), and higher
relative bioavailability values than subjects who were relapse free. The0
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Fig. 6. Primaquine pharmacokinetics in wild-type and CYP 2D knockout mice. Plasma and liver
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knockout mice are indicated by the dashed line. This ﬁgure was adapted from (Potter et al., 20proﬁles and pharmacokinetic parameters of carboxyprimaquine in
humanswere unaffected by CYP 2D6 genotype supporting the evidence
that that formation of the carboxy metabolite proceeds via MAO-A
as the primary metabolic enzyme and has little to do with CYP 2D6
activated efﬁcacy.
The proﬁling of primaquine pharmacokinetics in a mouse model of
differential CYP 2D6 metabolism was conducted by Potter et al.
(2015) and the corresponding trends were similar to that obtained by
Bennett et al. (2013) in the human study. The plasma and liver pharma-
cokinetic proﬁles of parent primaquine in normal wild-type C57 BL/6
and CYP 2D knock-out mice (Fig. 6A and B; Potter et al., 2015) show
parent primaquine levels were lowest in the wild type mice for both
plasma and liver tissue. Parent primaquine levels were elevated in the
CYP 2D knockout animals. These results are consistent with the Bennett
human data and indicate that reduced or null CYP 2D6 activity greatly
impacts the ﬁrst past metabolism effect for primaquine metabolism
and greatly alters systemic exposure of the parent drug. In addition to
parent primaquine levels, this work provided insight into CYP 2D
mediated production of the primaquine phenolic metabolites that are
likely responsible for primaquine efﬁcacy and toxicity. Potter et al.
(2015) only observed high levels of primaquine phenolic metabolites
in the wild-type mice that were capable of CYP 2D metabolism as
illustrated in Fig. 6 C and D for the 4-hydroxyprimaquine and the 5,6-
orthoquinonemetabolites. This is in contrast to the very small amounts
of the same phenolic species produced in the CYP 2D knockout mice
indicating a very low level production of these compounds by non-
CYP 2D pathways.
The pharmacokinetic results from the human and mouse studies
help paint a picture of the pharmacokinetic proﬁle of primaquine and
primaquine reactive metabolites in the context of CYP 2D6metabolism.
This concept is highlighted in Fig. 7 for the likely pharmacokinetic out-
comes of administering primaquine to various CYP 2D6 metabolizers.
Fig. 7A illustrates the pharmacokinetics of primaquine administered to
a CYP 2D6 poor metabolizer. The parent drug levels (black curve) in
these people would be the highest as compared to other metabolizer0
5,000
10,000
15,000
0 2 4 6 8
0
500
1,000
1,500
2,000
0 2 4 6 8
Phenolic Metabolite PK
Liver
Liver
Co
nc
en
tra
tio
n 
(ng
/m
L)
Co
nc
en
tra
tio
n 
(ng
/m
L)
4-OH-PQ
5,6-ortho-quinone
Time Post Dose (Hours)  
Time Post Dose (Hours)  
pharmacokinetics of primaquine tested in the samemouse strains utilized for the efﬁcacy
imaquine in wild type mice are indicated by the red line, while the plasma and liver
shed line. (C–D)The liver pharmacokinetic proﬁles of primaquine phenolic metabolites
e liver pharmacokinetic proﬁles of the primaquine phenolic metabolites in the CYP 2D
15) with permission.
Active Metabolite(s) 
Pharmacokinetics
Parent Primaquine
Pharmacokinetics
Predicted Clinical 
Outcome
Clinical Failure
Relapse of P. Vivax 
Outcome Uncertain: 
Confounding factors 
Including:
enzyme activity, body 
weight, dose, transport
Clinical Success
Radical Cure
of P. Vivax 
CYP 2D6 
Metabolizer  Status
Poor 
Metabolizer
Intermediate 
Metabolizer
Extensive 
Metabolizer
Co
nc
en
tra
tio
n
Time
Co
nc
en
tra
tio
n
Time
Co
nc
en
tra
tio
n
Time
Co
nc
en
tra
tio
n
Time
Co
nc
en
tra
tio
n
Time
Co
nc
en
tra
tio
n
Time
A
B
C
Therapeutic Window
Therapeutic Window
Therapeutic Window
Fig. 7. Predicted pharmacokinetic/clinical response to primaquine therapy. Predicted for (A.) CYP 2D6 poor metabolizer, (B.) intermediate metabolizers, and (C.) extensive metabolizers.
The predicted pharmacokinetic responses for parent primaquine and active metabolite(s) and likely clinical outcomes are indicated in each scenario.
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there would be little to no production of the reactive metabolite(s)
(red curve) responsible for efﬁcacy. The clinical outcome in this scenario
would likely be relapse and primaquine failure as demonstrated previ-
ously in humans (Bennett et al., 2013; Ingram et al., 2014). The treat-
ment options for vivax infection in poor metabolizer are likely limited.
For individuals with no CYP 2D6 activity and infected with Plasmodium
vivax, the clinical manifestations of infectionwould have to bemanaged
with alternative antimalarials such as chloroquine, artemether/
lumefantrine as was done previously for primaquine failures (Bennett
et al., 2013; Ingram et al., 2014). These individuals would likely suffer
several relapses before their immune systems would eliminate the
infection. Additionally, the use of primaquine as a prophylactic agent
in this population would likely be ineffective and alternative drugs
should be considered (Deye & Magill, 2014).
Intermediate CYP 2D6 metabolizer primaquine pharmacokinetics is
illustrated in Fig. 7B. These individuals would have parent primaquine
and reactive metabolite levels that fall between that of the poor and
extensive metabolizers. The clinical outcome for this group is difﬁcult
to predict as there are several confounding factors to include; severity
of CYP 2D6 enzyme deﬁciency, total bodyweight, and total dose admin-
istered. As indicated above for poormetabolizer individualswho relapse
while on primaquine therapy, clinicians need to consider treating
clinical manifestations of the infection with alternative antimalarials.
For both the intermediate and poor metabolizers, alternative
therapies/prophylactic agents to primaquine and patient education to
seek medical treatment if malaria symptoms arise/return seem to be
the best courses of action (Deye & Magill, 2014).
The predicted pharmacokinetics of primaquine in humans that are
extensive metabolizers is shown in Fig. 7C. These individuals would
have the lowest parent primaquine levels and highest production of
reactive metabolites as compared to the other two groups discussed.Primaquine therapy would likely be successful in this group. An addi-
tional group of individuals would fall into a category of ultra-rapid
metabolizers (pharmacokinetic scenario not shown). These individuals
would display the most primaquine metabolism through the CYP 2D6
pathway; however, the clinical outcome of primaquine therapy in this
group remains to be determined as there is no current animal or
human data from ultra-rapid metabolizer geno/phenotypes.
7. CYP 2D6 mediated primaquine drug–drug interactions
The involvement of CYP 2D6 metabolism for any therapeutic area
is problematic not only due to genetic polymorphisms, but, for the
potential of CYP 2D6 mediated drug–drug interactions. Primaquine
seems to be no different as there are several documented instances
of pharmacokinetic drug–drug interactions in the literature (Alving
et al., 1955; Hanboonkunupakarn et al., 2014; Jin et al., 2014;
Pukrittayakamee et al., 2014; Jittamala et al., 2015). The most studied
of these interactions is between primaquine and blood stage
anti-malarial agents administered concurrently. The blood stage agents
chloroquine, dihydroartemisinin-piperaquine combination, and
pyronaridine-artesunate combination have been shown to alter
the pharmacokinetics of primaquine when co-administered
(Hanboonkunupakarn et al., 2014; Pukrittayakamee et al., 2014;
Jittamala et al., 2015). Interestingly, pyronaridine–artesunate combina-
tion therapy, chloroquine, and dihydroartemisinin have all been
shown to alter the pharmacokinetics and metabolism of the CYP 2D6
probe substrate metoprolol (Asimus et al., 2007; Lancaster et al., 1990;
Morris et al., 2014). These studies linked inhibition of CYP 2D6 by
various antimalarials as the cause of increased metoprolol levels
and decreased production of the CYP 2D6 dependent metabolite
alpha-hydroxymetoprolol. Similar results were obtained for parent
primaquine pharmacokinetics with concurrent administration
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pyronaridine–artesunate combination therapy (Hanboonkunupakarn
et al., 2014; Pukrittayakamee et al., 2014; Jittamala et al., 2015). The
primaquine plasma levels and exposure were the highest upon combi-
nation with these blood stage agents. This is likely due to the alteration
of CYP 2D6 primaquinemetabolism by the co-administered blood stage
agents. The effect on primaquine phenolic metabolite production,
particularly the 5,6-orthoquinone marker of 5-hydroxy primaquine
has not been investigated with regard to the above combinations and
should be considered in future human primaquine pharmacokinetic
studies. While there are primaquine pharmacokinetic alterations due
to drug–drug interactions, the impact that these drug–drug interactions
have on primaquine efﬁcacy is unclear. There have been several studies
that have analyzed the efﬁcacy of primaquine in the context of
concurrent blood stage agent administration (Alving et al., 1955;
Alvarez et al., 2006; Sutanto et al., 2013; Nelwan et al., 2015). The
original and most notable of these studies was conducted over
60 years ago by Alving et al. (1955). This study is intriguing as the
authors observed a potentiation effect on primaquine radical curative
efﬁcacy when co-administered with quinine or chloroquine. Alterna-
tively, Sutanto et al. (2013) demonstrated that concurrent quinine
administration (quinine is a potent CYP 2D6 inhibitor) with a therapeu-
tic dose of primaquine was less efﬁcacious than primaquine co-
administered with dihydroartemisinin-piperaquine. It is interesting to
note that primaquine remained efﬁcacious (mid to low 90% efﬁcacious)
in all of these studies despite co-administration with potential CYP 2D6
inhibitors. These studies did have subjects who relapsed, however, the
causes for these relapses are unknown. The role of CYP 2D6metabolism
cannot be dismissed in these studies as they were not designed to
examine the potential for CYP 2D6 mediated drug–drug interactions
and/or other pharmacogenomic alterations. Additional confounding
factors that could inﬂuence CYP 2D6 mediated primaquine drug–drug
interactions are the variable pharmacological parameters of the co-
administered drugs such as half-life and overall systemic exposure.
Such factors would inﬂuence the extent and duration of any CYP 2D6
mediated interactions. Other confounding factors that add to the
complexity of studying primaquine interactions is the likelihood of
transporter mediated drug–drug interactions. Primaquine has been
shown to interact with ABC transporters such as P-glycoprotein
(Ambudkar et al., 1999; Hayeshi et al., 2006; Jin et al., 2014). P-
glycoprotein mediated transport can inﬂuence drug absorption and
distribution. Interestingly, some of the blood stage antimalarial agents
that could interact with primaquine through CYP metabolic pathways,
also have the potential to interact with primaquine through
P-glycoprotein mediated transport (Ambudkar et al., 1999; Hayeshi
et al., 2006; Jin et al., 2014). Primaquine drug–drug interactions are
likely complex and involve a multitude of pharmacological factors
besides hepatic metabolism. The safety and efﬁcacy of future
primaquine combination therapies should be examined through well
controlled clinical trials that account for factors such as variable CYP
2D6 pharmacogenomics and P-glycoprotein mediated transport.
8. Conclusions and future directions
8.1. Implications from CYP 2D6/primaquine link
Like most successful research endeavors, the CYP 2D6/primaquine
discovery raises more questions than it has answered. Such questions
center around whether 2D6 mediated hepatic metabolism of
primaquine results in the associated hemolytic toxicity and whether
the same metabolic pathway responsible for efﬁcacy is also responsible
for hemolytic toxicity? Is hepatic metabolism required for primaquines'
gametocidal activity? Is primaquine efﬁcacy susceptible to CYP 2D6
mediated drug–drug interactions of clinical signiﬁcance? Such
questions are important to be addressed clinically as these issues
could guide future primaquine therapy and administration guidelinesfor malaria elimination and eradication campaigns. Accordingly, these
questions should be addressed by themalaria community using the var-
iousmalaria animal models and controlled human clinical trials. Recent
advances in in vitro drug metabolism andmalaria infection models will
hopefully allow formore complete and expedited investigations of such
questions (Furuya et al., 2014; Ng et al., 2015; Yang et al., 2015).
The CYP 2D6/primaquine discovery also provides clinicians an addi-
tional avenue to address possible causes of relapse despite primaquine/
8-aminoquinoline therapy. CYP 2D6 genotyping is readily available
through multiple diagnostic vendors in addition to purchasable kits.
Determining an individual's CYP 2D6 genotype in relation to relapse
could inform clinicians to opt for alternative treatment options to
manage relapses and better inform patients. Additionally, the CYP
2D6/primaquine link allows physicians and pharmacists to be more
conscientious and aware of possible CYP 2D6 mediated drug–drug
interaction as possible causes for primaquine therapy failures. Further-
more, awareness of the CYP 2D6/primaquine link is important to
considerwhen primaquine failures are observed clinically. Often clinical
failures with malaria treatment are commonly attributed to the
emergence of drug resistance, however, in the case of primaquine, it is
important to investigate the phenotype of individuals failing
primaquine treatment to determine if the drug failure is the result of
poor metabolic activation rather than the emergence of resistance to
primaquine.
In lieu of CYP 2D6 genotyping prediction of primaquine phenotype,
there is also a need for phenotypic data for primaquine in relation to
known CYP 2D6 genotypes. Such phenotypic correlation can be done
using primaquine/phenolic metabolite ratios compared in the various
CYP 2D6metabolizer classiﬁcations. This would allow for a direct corre-
lation with genotype. Currently, primaquine phenotype prediction
based on genotype can vary depending on the classiﬁcation system
used for prediction. This is highlighted in the two classiﬁcations systems
used in the two human primaquine relapse examples published
(Bennett et al., 2013; Ingram et al., 2014). Both studies used the CYP
2D6 activity scoring system (AS-Score) for phenotype prediction; how-
ever, Bennett et al. (2013) used the predicted phenotype cut-off criteria
of poor metabolizers AS score = 0, intermediate metabolizers AS
score = 0.5, and extensive metabolizers AS score of 1–2, while Ingram
et al. (2014) used the predicted phenotype cut-off criteria of poor
metabolizers AS score = 0, intermediate metabolizers AS score = 0.5–
1, and extensive metabolizers AS score of 1.5–2. These differences in
study design and CYP 2D6 metabolizer classiﬁcation will ultimately
make comparing CYP 2D6/8-aminoquineoline pharmacology studies
difﬁcult.
8.2. The need for the development of
non-CYP 2D6 metabolized liver stage agents
In addition to addressing the questions raised above, there is a
need for the development of liver stage/radical curative antimalarial
drugs that do not require metabolism by polymorphic CYP enzymes.
Currently, there are no drug candidates in the drug development
pipeline that are radical curative that do not seem to require hepatic
metabolism. The only other 8-aminoquineoline that is close to ﬁelding
and under late stage development for radical cure is tafenoquine.
Tafenoquine is a single dose radical curative agent that is a promising
alternative to primaquine, however, tafenoquine might also require
hepatic metabolism for efﬁcacy as indicated by pre-clinical testing in
animalmodels (Marcsisin et al., 2014; Vuong et al., 2015). The deﬁnitive
link between tafenoquine liver stage anti-malarial activity and CYP 2D6
metabolism has yet to be established in humans and is currently being
actively investigated (St Jean et al., 2016). That being said, there is a
need for the discovery and development of new safer antimalarial
agents that treat relapsing strains of malaria and do not require CYP
2D6 metabolism for activity. Such drugs would be invaluable tools in
the ﬁght against malaria.
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